Evidence map›Paper›PMID 27821443›Full record

ArticleAntimicrobial agents and chemotherapy2017

Altered Plasmodium falciparum Sensitivity to the Antiretroviral Protease Inhibitor Lopinavir Associated with Polymorphisms in pfmdr1.

Ebere Sonoiki, Christian Nsanzabana, Jennifer Legac, Kirthana M V Sindhe, Joseph DeRisi, Philip J Rosenthal

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02282293 (Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02282293 phase3completednot on this map

Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE Birth Cohort 2)

TypeinterventionalSponsorUniversity of California, San FranciscoRan2014 to 2016Enrolled200ConditionsMalaria, Human Immunodeficiency VirusArmsMonthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS), Monthly placebo + daily trimethoprim/sulfamethoxazole (TS)
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Antimicrobial agents and chemotherapy · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ebere SonoikiDepartment of Medicine, University of California, San Francisco, California, USA.
Christian NsanzabanaDepartment of Medicine, University of California, San Francisco, California, USA.
Jennifer LegacDepartment of Medicine, University of California, San Francisco, California, USA.
Kirthana M V SindheDepartment of Medicine, University of California, San Francisco, California, USA.
Joseph DeRisiHoward Hughes Medical Institute and the Department of Biochemistry and Biophysics, University of California, San Francisco, California, USA.ORCID 0000-0002-4611-9205
Philip J RosenthalDepartment of Medicine, University of California, San Francisco, California, USA philip.rosenthal@ucsf.edu.
University of California, San Francisco · USHoward Hughes Medical Institute · US

Funding

The immunologic consequences of prenatal exposure to malariaP01HD059454 · NICHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 2008 to 2017
$22.6M
Howard Hughes Medical InstituteNICHD NIH HHS P01 HD059454
6 · The paper itself

Abstract

The HIV protease inhibitor lopinavir inhibits Plasmodium falciparum aspartic proteases (plasmepsins) and parasite development, and children receiving lopinavir-ritonavir experienced fewer episodes of malaria than those receiving other antiretroviral regimens. Resistance to lopinavir was selected in vitro over ∼9 months, with ∼4-fold decreased sensitivity. Whole-genome sequencing of resistant parasites showed a mutation and increased copy number in pfmdr1 and a mutation in a protein of unknown function, but no polymorphisms in plasmepsin genes.

Indexed as

GenomeAntimalarialsAspartic Acid EndopeptidasesATP-Binding Cassette, Sub-Family C ProteinsDrug ResistanceErythrocytesGene ExpressionHigh-Throughput Nucleotide SequencingHIV Protease InhibitorsHumansInhibitory Concentration 50LopinavirMutationPlasmodium falciparumProtozoan ProteinsAntimalarialsAspartic Acid EndopeptidasesATP-Binding Cassette, Sub-Family C ProteinsHIV Protease InhibitorsLopinavirMdr1 protein, Plasmodium falciparumplasmepsinProtozoan Proteinsantiretroviralaspartic proteasedrug resistancedrug resistance mechanismsdrug sensitivityHIVlopinavirmalariapfmdr1Plasmodium falciparum

Identifiers

PMID27821443
PMCPMC5192118
OpenAlexW2549322832

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.